A partial fragment of novel sequence (arr, adriamycin-resistant related) was previously identified using the differential display (DD)-PCR technique with adriamycin-resistant L1210 variant (L1210AdR), which shows a typical multidrug resistant (MDR) phenotypes. The present research shows the isolation of full length arr cDNA sequence. To clone the full length cDNA of arr gene, DD-PCR fragments were subjected to 5'- and 3'-Rapid Amplification of cDNA End (RACE) method. The cloned arr cDNA consisted of 770 bases and contained an open reading frame of 153 bases, encoding a protein of 51 amino acid with the molecular mass of 4 kDa by in vitro translation reactions. Northern blot analysis showed that a 770 bases transcript arr gene was overexpressed in adriamycin-resistant L1210 variant, but not in the parent suggesting that the arr gene may be involved in the adriamycin-resistant phenotypes.
Amino Acid Sequence ; Animal ; Base Sequence ; Blotting, Northern ; Cloning, Molecular ; DNA Primers ; Doxorubicin/pharmacology* ; Drug Resistance, Neoplasm/genetics* ; Gene Expression Regulation, Neoplastic ; Glycoproteins/genetics* ; Leukemia L1210/genetics* ; Leukemia L1210/drug therapy ; Mice ; Molecular Sequence Data ; Translation, Genetic

To improve the physical property and bioactivity of methotrexate, this paper investigated the new formation of conjugate methotrexate-poly (ethylene glycol) and in vitro anti-tumor activity of the synthesized conjugate. The conjugate of methotrexate-poly (ethylene glycol), which was verified by the spectroscopy analysis of UV, IR and 13C NMR, was synthesized by chemical catalysis and micro-wave irritation. The determination for the conjugate of solubility in water and distribution coefficient in octanol-water system of the conjugate was done to examine its deliquescence property. The solubility in water and the distribution coefficient of the conjugate was greatly improved, which was increased by 128 folds and 5 folds, respectively. The in vitro anti-tumor activity of the conjugate was tested by mouse L(1210) leukaemia cells, and the synthesized conjugate showed the same anti-tumor activity as the original methotrexate. Compared to the reported literature, the modification of methotrexate by poly (ethylene glycol) is more rapid and convenient.
Animals ; Antineoplastic Agents ; chemical synthesis ; Leukemia L1210 ; drug therapy ; Methotrexate ; chemical synthesis ; chemistry ; pharmacology ; Mice ; Polyethylene Glycols ; chemical synthesis ; chemistry ; pharmacology ; Solubility

The objective of this study was to investigate the expression and function of indoleamine 2, 3-dioxygenase (IDO) in leukemia. The IDO expressions in human acute monocyte leukemia (M(5)) and acute lymphocyte leukemia (ALL) were detected by immunofluorescence staining. Constructed leukemia mouse model was used to observe whether the IDO inhibitor, 1-methyl tryptophan (1-MT), has any effect in treating leukemia. The experimental group were fed with 1-MT solution every day while the mice in control group had no further treatment. The results showed that the average ratios of IDO expression were 29.4 +/- 11.2% in M(5) patients and 24.7 +/- 7.96% in ALL patients respectively. After statistical test, IDO expression level in leukemia cells was significantly higher than that of normal mononuclear cells. The tumor decreased gradually in mice treated with 1-MT. At the terminal point of the experiment (88 days after vaccination), the average survival time in the experimental group was 42.3 days while the mice in control group only lived 15.1 days in average, which difference was statistically significant (P < 0.05). Some of the leukemia mice in the experimental group long-term survived without tumor (more than three months after vaccination). It is concluded that human acute monocyte leukemia (M(5)) and acute lymphocyte leukemia (ALL) express IDO, and both can be treated by 1-MT in mice.
Adolescent ; Adult ; Animals ; Child ; Female ; Humans ; Indoleamine-Pyrrole 2,3,-Dioxygenase ; antagonists & inhibitors ; metabolism ; Leukemia L1210 ; drug therapy ; Leukemia, Biphenotypic, Acute ; drug therapy ; enzymology ; Leukemia, Monocytic, Acute ; drug therapy ; enzymology ; Male ; Mice ; Mice, Inbred DBA ; Middle Aged ; Tryptophan ; analogs & derivatives ; therapeutic use ; Young Adult